Core Viewpoint - The article emphasizes the launch of a three-year "Weight Management Year" initiative by the National Health Commission to promote healthy living and address the rising obesity rates in China [3][5]. Group 1: Background and Context - The initiative is part of the "Healthy China 2030" strategy, aiming to create a supportive environment for weight management nationwide [5]. - The prevalence of overweight and obesity among Chinese adults is alarming, with over half of the adult population classified as overweight (34.3%) or obese (16.4%) [11]. - The report predicts that by 2030, the obesity rate among adults in China could reach 65.3% [11]. Group 2: Health Risks Associated with Obesity - Obesity is linked to various chronic diseases, including hypertension, diabetes, cardiovascular diseases, and certain cancers [5][12]. - The World Health Organization identifies obesity as the fifth leading risk factor for global health [12]. - Medical expenses related to overweight and obesity in China are projected to reach 418 billion RMB by 2030, accounting for 21.5% of national healthcare costs [12]. Group 3: Guidelines for Weight Management - The article outlines the definition of overweight and obesity based on Body Mass Index (BMI) standards, with a BMI of 24-28 classified as overweight and 28 or above as obese [7]. - It stresses the importance of personal responsibility in managing weight and adopting a healthy lifestyle [5][23]. - Effective weight management should follow three principles: safety, effectiveness, and comprehensive prevention [22]. Group 4: Strategies for Weight Loss - The core principle of weight loss is to consume fewer calories and increase physical activity, creating a negative balance in fat storage [21]. - The article encourages immediate action to enhance health awareness and suggests that the use of GLP-1 medications could help reverse the obesity trend in the next decade [22].

Core Viewpoint - Protagonist Therapeutics has selected PN-477 as its primary development candidate for obesity treatment, which is a triple agonist peptide targeting GLP-1, GIP, and glucagon (GCG) receptors, offering both efficacy and convenience through oral or subcutaneous administration [2][4]. Group 1: Drug Development and Efficacy - PN-477 has completed extensive preclinical evaluations, demonstrating positive effects in various animal models of obesity and blood glucose control, including diet-induced obese mice, normal dogs, and crab-eating macaques [4]. - The drug exhibits strong activation of GLP-1, GIP, and GCG receptors in vitro, indicating its potential effectiveness [4]. - PN-477's pharmacodynamic properties and overall performance make it suitable for parallel development as both a daily oral medication (PN-477o) and a weekly injection (PN-477sc) [4]. Group 2: Clinical Trials and Future Plans - The Investigational New Drug (IND) application is currently underway, with the first phase of clinical trials expected to start in the second quarter of 2026 [4]. - Protagonist Therapeutics plans to submit a New Drug Application (NDA) for its other candidates in 2025, indicating a robust pipeline [6][7]. Group 3: Market Position and Competitive Advantage - Despite the dominance of GLP-1 receptor agonists in the market, there is room for improvement, and a triple agonist like PN-477 could provide a significant breakthrough in obesity treatment by offering an oral option alongside injectable therapies [6]. - PN-477 is anticipated to reduce fat mass while preserving lean body mass and improving tolerability and comorbidities, positioning it as a potential blockbuster product for the company [6]. Group 4: Company Overview - Protagonist Therapeutics is an integrated biopharmaceutical company focused on drug discovery and late-stage development, with two novel candidates in Phase III clinical trials and plans for NDA submissions in 2025 [6][7]. - The company is also advancing several preclinical peptide drug development projects, including PN-881 and oral hepcidin [7].

Core Viewpoint - Obesity is a chronic metabolic disease that poses significant health risks, including the development of various serious chronic diseases such as diabetes, coronary heart disease, and stroke. The perception of obesity as merely a personal behavior issue is misleading, as societal changes have contributed to a rapid increase in obesity rates in China, making it the country with the fastest-growing prevalence of overweight and obesity globally [3][4]. Summary by Sections Understanding Obesity - Obesity is not just a simple condition but a complex health issue with various classifications based on genetic, metabolic, and anatomical factors. The World Health Organization (WHO) defines obesity with a BMI threshold of ≥30.0 kg/m², while Chinese guidelines set it at ≥28 kg/m². This classification reflects the need for a nuanced understanding of obesity beyond mere weight [5][6]. Health Risks Associated with Obesity - Obesity significantly increases the risk of developing type 2 diabetes, hypertension, sleep apnea, and can lead to a reduction in life expectancy by 6 to 14 years. The healthy BMI range for adults is defined as 18.5-23.9 kg/m², and exceeding this range indicates potential health risks [4][5]. Types of Obesity - Obesity can be categorized into various types, including genetic obesity, acquired obesity, central obesity, and peripheral obesity. The modern classification emphasizes clinical practicality, distinguishing between metabolically healthy and unhealthy obesity, and recognizing the importance of identifying underlying pathological factors [5][6]. Specific Conditions Related to Obesity - **Hypothyroidism**: Often goes unnoticed due to its subtle symptoms, which include weight gain, fatigue, and cold intolerance. Early recognition is crucial for effective management [6]. - **Cushing's Syndrome**: Characterized by excessive cortisol levels, leading to central obesity and other systemic complications. Early identification of its clinical features is vital for timely treatment [9][10]. - **Polycystic Ovary Syndrome (PCOS)**: A prevalent endocrine disorder among women in China, with a high incidence of hyperandrogenism, leading to abdominal obesity and insulin resistance [11][12]. - **Genetic Obesity**: Rare but significant, often linked to specific genetic mutations affecting energy metabolism. Early diagnosis through genetic testing can guide treatment [12][14]. Contributing Factors to Obesity - **Medication-Induced Obesity**: Certain medications, including those for diabetes and psychiatric conditions, can lead to weight gain. Identifying these medications is essential for effective weight management [17]. - **Psychological Factors**: Increased anxiety and stress in modern society contribute to unhealthy eating behaviors and sedentary lifestyles, exacerbating obesity [18]. - **Gonadal Dysfunction**: Can lead to complex clinical presentations, including obesity, and requires careful evaluation for effective management [19]. Conclusion - Recognizing obesity as a chronic condition requiring long-term management is essential. Understanding the multifaceted causes of obesity can help in developing targeted interventions to prevent related complications and promote healthier lifestyles [20].

以下文章来源于内分泌早知道 ，作者关注内分泌的 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展。 内分泌早知道 . 近年来，随着健康意识的普及，低碳水化合物饮食（LCDs）已成为减肥界的新宠，但其实际效果却引发学界持续争论。传统观点认为 严格控制碳水化合物摄入能有效减重，然而哈佛大学公共卫生学院发表在《JAMA Ne two r k Op e n》的最新研究揭示了一个关键发现： 并非所有低碳水饮食都能帮助减肥，饮食质量才是决定成败的核心因素。这项覆盖1 2万余名受试者的大规模研究指出，以动物蛋白和精 制脂肪为主的低碳水饮食不仅减重效果有限，反而可能导致体重快速反弹。 研究团队通过长达2 4年的追踪观察发现，选择植物性蛋白、健康脂肪和全谷类食物的高质量低碳水饮食者，其体重维持效果显著优于传 统低碳水饮食组。更令人意外的是，那些偏好红肉、加工食品的低碳水饮食者，其体重增长幅度甚至超过了普通饮食人群。这一发现彻 底颠覆了"只要减少碳水就能减肥"的固有认知，证实了食物来源和质量对体重管理的决定性作用。科学家强调，单纯计算碳水化合物含 量而忽视食物营养构成的减肥方式，很可能适得其反。该研究 ...

Core Viewpoint - The combination of Bimagrumab and Semaglutide shows significant efficacy in weight management, with an average weight loss of 22.1% over 48 weeks, primarily from fat reduction, indicating a comprehensive strategy for obesity treatment [2][4]. Group 1: Clinical Trial Results - In a 48-week trial, participants receiving the combination treatment lost an average of 22.1% of their body weight, with 92.8% of this loss attributed to fat reduction, compared to a 15.7% weight loss with Semaglutide alone, where 71.8% was fat loss [2]. - The combination therapy not only resulted in greater weight loss but also preserved more lean body mass, which is particularly important for populations at risk of sarcopenia [4]. Group 2: Significance of the Research - The study addresses a major public health issue, as obesity is linked to various complications such as diabetes, heart disease, and certain cancers, and the combination therapy may improve the quality of life for many patients [4]. - Bimagrumab's development is part of Eli Lilly's ongoing innovation strategy in obesity treatment, focusing on the often-overlooked issue of muscle preservation during weight loss [4]. Group 3: Future Directions - Eli Lilly is also advancing clinical trials for Bimagrumab in combination with Zepbound, a dual-target GLP-1/GIP agonist, expanding treatment options for patients and healthcare providers [5]. - The acquisition of Versanis Bio for approximately $2 billion highlights the company's commitment to exploring new avenues in weight management, particularly targeting ActRII [6]. Group 4: Mechanism of Action - Bimagrumab targets the activin receptor type II (ActRII), which plays a crucial role in muscle growth regulation, and its inhibition may provide a more effective approach to preserving muscle mass during weight loss [12][13]. - The signaling pathway involving ActRII has implications for muscle diseases, and targeting this receptor could lead to advancements in treating conditions like sarcopenia and cachexia [9][13].

Core Viewpoint - Wave Life Sciences Ltd. presents promising preclinical data for its candidate drug WVE-007, which targets INHBE mRNA to reduce fat mass without compromising muscle quality, potentially lowering the risk of metabolic diseases such as type 2 diabetes and coronary artery disease [1][7]. Group 1: Mechanism and Efficacy - WVE-007 is a GalNAc-modified siRNA that significantly downregulates INHBE mRNA and its product Activin E protein, which inhibits fat breakdown in obesity [2]. - A single administration of WVE-007 results in weight loss comparable to the widely used GLP-1 receptor agonist semaglutide [3]. - The drug effectively reduces visceral fat, decreases adipocyte size, and preserves muscle mass, supporting weight loss through the restoration of adipose tissue function [4]. Group 2: Inflammatory Response - WVE-007 significantly inhibits the recruitment of pro-inflammatory M1 macrophages while maintaining levels of anti-inflammatory M2 macrophages, demonstrating strong anti-inflammatory potential [5]. Group 3: Combination and Maintenance Therapy - When used in conjunction with semaglutide, INHBE-siRNA can double the weight loss effect, indicating a synergistic therapeutic potential [6]. - After discontinuation of semaglutide, INHBE-siRNA significantly slows weight regain, suggesting it could serve as a maintenance or transitional therapy for GLP-1 treatments [7]. Group 4: Genetic Insights and Future Prospects - Individuals carrying INHBE gene loss-of-function variants often exhibit healthier metabolic profiles, including reduced abdominal fat, lower triglyceride levels, and decreased risks of type 2 diabetes and cardiovascular diseases [7]. - The Chief Scientific Officer of Wave emphasizes that if clinical trials confirm these mechanisms, WVE-007 could revolutionize obesity treatment by offering a new pathway that requires only one to two injections per year for healthy weight loss while preserving muscle mass [7].

Core Viewpoint - The article emphasizes the increasing prevalence of obesity in China and the need for effective weight management strategies in line with the "Healthy China 2030" initiative. It highlights the importance of lifestyle changes over temporary dieting methods for sustainable weight loss. Group 1: Obesity Trends - The global obesity rate has surpassed that of underweight individuals, with China having the highest number of obese individuals, exceeding 89.6 million in 2016 [5][11] - Over 50% of adults in China are classified as obese, with nearly 20% of children and adolescents also affected [5][13] - The rise in obesity is attributed to various factors, including genetic predisposition, lifestyle habits, and societal changes that promote sedentary behavior and unhealthy eating [11][12] Group 2: Challenges in Weight Loss - Many popular weight loss methods, such as intermittent fasting, often lead to temporary results and can result in weight regain [6][20] - Psychological factors, such as emotional eating, complicate the weight loss journey, making it difficult for individuals to maintain their goals [12][19] - The article stresses that successful weight management requires a comprehensive approach that includes behavioral changes and medical intervention when necessary [18][21] Group 3: Recommended Strategies for Weight Management - A successful weight loss strategy should focus on lifestyle changes, including adequate sleep, regular self-monitoring of weight, and a balanced diet low in salt, oil, and sugar [22][23] - The article advocates for a balanced approach to diet, emphasizing the importance of consuming whole grains and high-fiber foods while avoiding refined sugars [25][27] - Regular physical activity is crucial, with recommendations for a mix of aerobic and strength training exercises to enhance weight loss and body composition [31][32]

整理 | GLP1减重宝典内容团队 6月27日，国家药品监督管理局官网显示，由信达生物研发的信尔美®（玛仕度肽注射液）获批上市，用于成人肥胖或超重患者的长期体重控 制，初始体重指数（BMI）为：BMI≥28kg/m²（肥胖）；或 BMI≥24kg/m²（超重），并伴有至少一种体重相关的合并症（例如高血糖、高血 压、血脂异常、脂肪肝、阻塞性睡眠呼吸暂停综合征等）。 【药品名称】 通用名称：玛仕度肽注射液 商品名称：信尔美® 英文名称：Mazdutide Injection 药品成份：本品活性成份为玛仕度肽。 药品性状：本品为澄清或几乎澄清，无色或几乎无色液体。 【适应症】 本品用于成人肥胖或超重患者的长期体重控制，其初始体重指数（BMI）为： BMI > 28 kg/m²（肥胖），或 本文即详细介绍这款药品的详细使用说明及相关注意事项。 ▍玛仕度肽注射液 说明书摘要 BMI > 24 kg/m²（超重）并伴有至少一种体重相关的合并症（例如高血糖、高血压、血脂异常、脂肪肝、高尿酸血症、负重关节疼痛、阻塞性 睡眠呼吸暂停综合征等）。 【规格】 | 容量 | 含量 | 类型 | | --- | --- | --- | ...

Core Viewpoint - The article emphasizes the importance of weight management as a public health issue, highlighting the increasing awareness of obesity and overweight as significant health risks rather than mere aesthetic concerns [2][5]. Group 1: Scientific Weight Management Standards - On July 4, a scientific weight management standard was jointly released by Peking University People's Hospital and Alibaba Health, aiming to provide structured nutritional management, exercise intervention, and medication treatment for overweight and obese individuals [3][5]. - According to the National Health Commission, the overweight rate among Chinese adults is 34.3%, and the obesity rate is 16.4%, indicating that one in three adults is overweight and one in six is obese [5]. - The scientific weight management standard is not a one-size-fits-all approach; it emphasizes personalized plans and long-term health management goals for individuals with a BMI of 24 or higher [7]. Group 2: Challenges in Weight Management - Many individuals do not recognize obesity as a condition requiring intervention, often resorting to self-directed weight loss methods like dieting, which delays seeking professional help and overlooks health risks [7]. - The article identifies information asymmetry and unscientific methods as core issues that hinder users in their weight management journey [9]. Group 3: Collaborative Initiatives - Alibaba Health plans to collaborate with pharmaceutical companies like Eli Lilly, Xinda, and Yino to launch a scientific weight management program, offering personalized doctor consultations and pharmacist services [9]. - Additionally, Alibaba Health has partnered with ZhongAn Insurance to introduce a "no weight loss, no compensation" service, providing up to 5,000 yuan in coverage for users purchasing related products [12].

Core Viewpoint - The article emphasizes the growing recognition of obesity as a medical condition rather than a personal failing, highlighting the need for systemic intervention and support in managing weight and related health issues [3][4][7]. Group 1: Current State of Obesity in China - As of 2018, the overweight rate among adults in China was 34.3%, with an obesity rate of 16.4%, translating to approximately 182 million adults suffering from obesity [3]. - Public perception often misattributes obesity to personal lack of discipline, which complicates access to medical support for those affected [3][9]. Group 2: Policy and Medical Response - The National Health Commission and the National Administration of Traditional Chinese Medicine plan to establish weight management clinics in hospitals by June 2025, aiming for comprehensive coverage [4]. - The "Weight Management Year" initiative is part of a broader public health strategy to enhance awareness and skills related to weight management across the population [11][21]. Group 3: Changing Perceptions and Treatment Approaches - A significant portion of the public (84%) attributes obesity to personal self-control issues, while only about 60% recognize genetic and environmental factors as contributors [7]. - New medications, such as GLP-1 receptor agonists, are changing the treatment landscape for obesity, allowing for more effective management of weight and associated metabolic conditions [16][18]. Group 4: Integrated Weight Management Systems - The article discusses the establishment of integrated weight management systems in hospitals, which include a multidisciplinary approach involving doctors, nutritionists, and health managers [12][14]. - The "1+3+N" model implemented in hospitals aims to provide comprehensive care from screening to treatment and management, reflecting a shift towards a more collaborative healthcare approach [12][14]. Group 5: Community and Societal Engagement - The article highlights the importance of community involvement in weight management, advocating for initiatives that promote healthy lifestyles at the family, community, and workplace levels [14][21]. - Public support for integrating obesity prevention into national health strategies is strong, with many favoring practical interventions like community fitness facilities [19][22].